Русский
Nederlandse taal
Deutsch
Francés
한국어
Português
Español
日本語
ไทย
Poly L Lactic Acid Filler
Ingredient: Poly-l-lactic acid 50%, Sodium carboxymethyl cellulose, Mannitol
Specification: 150mg, 180mg,350mg
Package: Bottle
Application Area: Combined to make water and light, tighten and lift the skin, stimulate collagen, fill wrinkles and so on.
Product Introduction：
Highly uniform microspheres minimize inflammatory reactions, leading to a lower risk of redness and swelling at the injection site. Compared to aseptic filling and EO sterilization, irradiation sterilization is a safer and more controllable method, as EO sterilization may leave residual substances. A higher molecular weight allows for a slower degradation process, extending the duration of efficacy for a sustained and natural skin-enhancing effect.
Product Display：
Product Details:
Type | PLLA Filler |
Ingredient | Hyaluronic 26mg/ml, hydroxyapatite 30% |
Specification | 150mg, 180mg,350mg |
Effect area | Different uses, different layers |
Application area | Combined to make water and light, tighten and lift the skin, stimulate collagen, fill wrinkles and so on |
How to choose | Moderate to severe naso-lip wrinkles |
Package | Bottle |
Storage | Cool, dry environment |
Recommended | 1-2 pc/time |
Recommended interval | 12-24 months |
Lasting time | 12-24 months |
Microsphere size | More uniform particle size; D10 is greater than 10μm |
Characteristic viscosity | 1.2-1.4dL/g |
Product Package:
Customer Feedback：
Raw Material Advantages：
Designed with a particle size distribution where D10 surpasses 10μm, D50 ranges from 15-30μm, and D90 remains below 50μm, at least 90% of the microspheres are within the 10-50μm range. Greater uniformity in particle size results in fewer inflammatory reactions and a reduced incidence of post-injection redness. Compared to EO sterilization, which may leave residues, irradiation sterilization offers a safer and more controlled alternative. With a molecular weight of 150,000-250,000 Da, the higher molecular weight enables a slower degradation process, extending its benefits for sustained and natural skin rejuvenation.
Development Process:
Company Introduction:
The PCL/PLLA synthesis process features low tin content (Sn <30 ppm), controllable molecular weight, and biocompatibility meeting medical-grade standards, supported by independently developed synthesis equipment that enables anhydrous, oxygen-free, kilogram-scale production. Additionally, industrial-grade raw materials are refined through the company's purification technology platform to produce sterile, pyrogen-free medical-grade materials, including but not limited to polysaccharides such as sodium hyaluronate, carboxymethyl starch, and carboxymethyl cellulose.
